Co-Authors
This is a "connection" page, showing publications co-authored by Carl Lavie and Fabian Sanchis-Gomar.
Connection Strength
5.222
-
Why is COVID-19 especially impacting the African American population? Ann Med. 2020 11; 52(7):331-333.
Score: 0.898
-
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients? Eur Heart J. 2020 07 01; 41(32):3092-3093.
Score: 0.890
-
Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection. Ann Intern Med. 2021 06; 174(6):885-886.
Score: 0.237
-
In Reply - Cardiorespiratory Fitness Attenuates the Impact of Risk Factors Associated With COVID-19 Hospitalization. Mayo Clin Proc. 2021 03; 96(3):823-824.
Score: 0.231
-
CT-Determined Maximum Pulmonary Artery to Ascending Aorta Diameter Ratio in Nonsevere COVID-19 Patients. Acad Radiol. 2021 03; 28(3):440-441.
Score: 0.231
-
Fit Is It in COVID-19, Future Pandemics, and Overall Healthy Living. Mayo Clin Proc. 2021 01; 96(1):7-9.
Score: 0.229
-
Cardiac Injury in COVID-19-Echoing Prognostication. J Am Coll Cardiol. 2020 11 03; 76(18):2056-2059.
Score: 0.228
-
Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. J Diabetes. 2020 Nov; 12(11):851-855.
Score: 0.228
-
Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection? Am J Cardiovasc Drugs. 2020 Oct; 20(5):413-418.
Score: 0.226
-
In reply- Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19. Mayo Clin Proc. 2020 11; 95(11):2561-2563.
Score: 0.226
-
Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clin Chem Lab Med. 2020 08 27; 58(9):1415-1422.
Score: 0.222
-
COVID-19 and obesity: links and risks. Expert Rev Endocrinol Metab. 2020 07; 15(4):215-216.
Score: 0.221
-
In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Mayo Clin Proc. 2020 07; 95(7):1553-1556.
Score: 0.221
-
Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. Mayo Clin Proc. 2020 07; 95(7):1445-1453.
Score: 0.221
-
Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. Curr Probl Cardiol. 2020 Aug; 45(8):100617.
Score: 0.220
-
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clin Proc. 2020 06; 95(6):1222-1230.
Score: 0.219
-
Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May - Jun; 63(3):390-391.
Score: 0.218
-
Coronavirus Disease 2019-Associated Coagulopathy. Mayo Clin Proc. 2021 01; 96(1):203-217.
Score: 0.057